HeartBeam Inc. (NASDAQ: BEAT) is advancing a technology platform designed to address a persistent challenge in cardiac care: pre-hospital delay. Many patients do not seek medical attention at the onset of symptoms such as intermittent chest pain or palpitations, and traditional electrocardiogram (ECG) testing is typically conducted in clinical environments that may not coincide with symptom onset. As a result, clinicians often lack the data needed for timely, informed decisions.
HeartBeam is working to close this gap with its HeartBeam System, a cable-free, high-fidelity ECG platform capable of capturing the heart’s electrical signals from three distinct directions for arrhythmia assessment. By collecting multidirectional signals, the system is intended to provide a more comprehensive representation of cardiac activity compared with conventional single-lead devices. The system uses a compact, credit-card-size, portable design with embedded electrodes, allowing patients to record ECG signals without adhesive patches or wires. This simplifies the user experience while maintaining the quality of data needed for clinical interpretation.
A key feature of the HeartBeam System is its ability to generate synthesized 12-lead ECG signals from these recordings, bringing clinical-grade data traditionally associated with hospital-based equipment into a portable format. The system is currently FDA cleared for arrhythmia assessment, and the company plans to submit for an indication expansion for heart attack detection in the future.
The technology could have significant implications for patients and the healthcare system. By enabling ECG data collection outside of medical facilities, HeartBeam aims to empower physicians to identify cardiac health trends and acute conditions earlier, directing patients to appropriate care. This could reduce the time between symptom onset and treatment, potentially improving outcomes for conditions like heart attack. For the broader industry, the shift toward portable, clinical-grade ECG monitoring represents an evolution in how cardiac care is delivered, moving from reactive, in-hospital testing to proactive, out-of-hospital monitoring.
HeartBeam holds 13 U.S. and 4 international issued patents related to its technology. The company is focused on redefining the future of cardiac health management by providing actionable heart intelligence wherever the patient is. For more information, visit www.HeartBeam.com.
